Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">EXACT Sciences follow up: Upgraded details — to Buy at The Benchmark Company; tgt raised to $27 (22.35 +2.44)The Benchmark Company upgrades EXAS to Buy from Hold and raises their tgt to $27 from $17 following earnings. Rev in Q4 expanded 144% to $35.2 million in Q4 and Cologuard coverage expanded to 72% of the addressable population by February 20. Gross margin expanded 400 bps sequentially, to 60.7%, as revenue collected per test expanded $20 sequentially, to $432, and firm calculates the average cost per test declined $10 sequentially to $169. The compliance rate held steady sequentially, at 67%. <strong>With favorable cost trends and Cologuard now covered for the majority of patients, firm increasingly sees Exact as a marketing platform for internally developed and potentially acquired diagnostics. Exact plans to present data for its developmental lung cancer blood test, at the AACR conference in April.</strong></td> </tr></table>"